Imaging Surrogates of Tumor Response to Therapy: Anatomic and Functional Biomarkers

被引：64

作者：

Zhao, Binsheng ^{[1
,2
]}

Schwartz, Lawrence H. ^{[2
]}

Larson, Steve M. ^{[2
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA

来源：

JOURNAL OF NUCLEAR MEDICINE | 2009年 / 50卷 / 02期

关键词：

response assessment; surrogate biomarker; functional/molecular imaging; volumetric CT; lung cancer; POSITRON-EMISSION-TOMOGRAPHY; CELL LUNG-CANCER; PROLIFERATION IN-VIVO; DNA FLOW-CYTOMETRY; F-18-FDG PET; PROSTATE-CANCER; METABOLIC MEASUREMENTS; COMPUTED-TOMOGRAPHY; MAGNETIC-RESONANCE; PROGNOSTIC VALUE;

D O I：

10.2967/jnumed.108.056655

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

This article addresses the current status of quantitative imaging as a surrogate biomarker for the assessment of tumor response to therapy with non-small cell lung cancer as an example. In addition, the article discusses the limitations of conventional response criteria in the new era of molecular-targeted agent for cancer treatment; the increasing need for more accurate and early response-assessment methods, particularly for volumetric CT; new tumor-specific radiotracers and molecular imaging technologies; and the future applications of molecular imaging with PET for studying various features of cancer metabolism, endocrine status, hypoxia, and oncofetal and differentiation antigens.

引用

页码：239 / 249

页数：11

共 81 条

[11] Positron tomographic assessment of androgen receptors in prostatic carcinoma [J].

Dehdashti, F ;

Picus, J ;

Michalski, JM ;

Dence, CS ;

Siegel, BA ;

Katzenellenbogen, JA ;

Welch, MJ .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (03) :344-350

[12]

DEHDASHTI F, 2008, BREAST CANC RES 0309

[13] Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone) [J].

Dehdashti, Farrokh ;

Grigsby, Perry W. ;

Lewis, Jason S. ;

Laforest, Richard ;

Siegel, Barry A. ;

Welch, Michael J. .

JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (02) :201-205

[14] Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses:: a phase I trial [J].

Divgi, Chaitanya R. ;

Pandit-Taskar, Neeta ;

Jungbluth, Achim A. ;

Reuter, Victor E. ;

Gonen, Mithat ;

Ruan, Shutian ;

Pierre, Christine ;

Nagel, Andrew ;

Pryma, Daniel A. ;

Humm, John ;

Larson, Steven M. ;

Old, Lloyd J. ;

Russo, Paul .

LANCET ONCOLOGY, 2007, 8 (04) :304-310

[15]

Erdi YE, 1997, CANCER, V80, P2505, DOI 10.1002/(SICI)1097-0142(19971215)80:12+<2505::AID-CNCR24>3.3.CO

[16]

2-B

[17] Expanding the use of magnetic resonance in the assessment of tumor response to therapy: Workshop report [J].

Evelhoch, J ;

Garwood, N ;

Vigneron, D ;

Knopp, N ;

Sullivan, D ;

Menkens, A ;

Clarke, L ;

Liu, GY .

CANCER RESEARCH, 2005, 65 (16) :7041-7044

[18]

FOWLER JS, 1981, J NUCL MED, V22, P376

[19] Imaging transgene expression with radionuclide imaging technologies [J].

Gambhir, SS ;

Herschman, HR ;

Cherry, SR ;

Barrio, JR ;

Satyamurthy, N ;

Toyokuni, T ;

Phelps, ME ;

Larson, SM ;

Balatoni, J ;

Finn, R ;

Sadelain, M ;

Tjuvajev, J ;

Blasberg, R .

NEOPLASIA, 2000, 2 (1-2) :118-138

[20] Radiosynthesis of 3′-deoxy-3′-[18F]fluorothymidine:: [18F]FLT for imaging of cellular proliferation in vivo [J].

Grierson, JR ;

Shields, AF .

NUCLEAR MEDICINE AND BIOLOGY, 2000, 27 (02) :143-156

← 1 2 3 4 5 6 7 8 9 →